ClinicalTrials.Veeva

Menu

Effects of Exoskeleton-Assisted Gait Training on Bone Health and Quality of Life

Craig Hospital logo

Craig Hospital

Status

Unknown

Conditions

Osteoporosis

Treatments

Device: Exoskeleton assisted gait training

Study type

Interventional

Funder types

Other

Identifiers

NCT02533713
2015P001535

Details and patient eligibility

About

This is a randomized clinical trial to quantify the effects of exoskeleton-assisted gait on the musculoskeletal system and health-related quality of life.

Full description

Investigators will test if exoskeleton-assisted ambulation confers skeletal benefits in a dose-dependent fashion. Investigators also will test if reintroduction of ambulation will be associated with improvements in quality of life due to improvements in mood, pain, and functional connectivity of emotional networks in the brain.

Enrollment

36 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 3 years or more after injury,
  • Non-ambulatory AIS A-D spinal cord injury (C7-T12),
  • 158-188 centimeters tall,
  • Weigh less than 100 kilograms,
  • Have a Modified Ashworth Scale (MAS) score of less than 3 in both lower extremities, and
  • Have sufficient upper body strength to complete sit to sit transfers.
  • Women of childbearing potential must agree to use contraceptive measures during participation in the study. They also will be required to have a negative pregnancy test (urine or serum) before receiving an imaging studies.

Exclusion criteria

  • Current enrollment in another clinical trial
  • Pregnancy
  • Anyone with an initial blood pressure>140/90 mmHg, orthostatic hypotension with symptomatic fall in blood pressure >30 mmHg when upright,
  • An active grade 2 or greater pressure ulcer that can be worsened by walking in the device,
  • Lower extremity contractures that interfere with the ability to wear the device,
  • An unhealed limb or pelvic bone fracture history of other neurological disease (e.g. stroke, peripheral neuropathy, myopathy),
  • Active treatment for epilepsy,
  • Current use of medications potentially affecting bone health (bisphosphonates, androgenic steroids, estrogenic steroids, lithium, glucocorticoid use for more than 3 months).
  • Subjects with MRI-incompatible implants, pumps, or neurostimulators will be excluded.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

36 participants in 2 patient groups

Immediate gait training
Experimental group
Description:
Participants assigned to this arm will begin Exoskeleton assisted gait training right away and will continue training for the first 6 months of the study.
Treatment:
Device: Exoskeleton assisted gait training
Delayed gait training
Other group
Description:
Participants assigned to this arm will not gait train for 6 months. They will engage in Exoskeleton assisted gait training for the last 6 months of the study.
Treatment:
Device: Exoskeleton assisted gait training

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems